Endo selling Mexico-based Grupo-Farmaceutico Somar

Endo International said it is selling Grupo-Farmaceutico SOMAR to Advent International for $124 million. 

Grupo-Farmaceutico is based in Mexico City and the transaction is expected to close by December.

"SOMAR is a leading player in the large, growing Mexican private generics market," Juan Pablo Zucchini, managing partner and Head of Latin American Healthcare practice at Advent International, said.

Managing Director in Advent’s Mexico City office, Enrique Pani, said, "We look forward to working with SOMAR’s talented management team to continue growing all of the company’s business lines."

Organizations in this Story

Advent International

Want to get notified whenever we write about Advent International ?
Next time we write about Advent International, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.